These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8902156)
41. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. Kojima S; Harada-Shiba M; Nomura S; Kimura G; Tsushima M; Kuramochi M; Yamamoto A; Omae T ASAIO Trans; 1991; 37(4):644-8. PubMed ID: 1768503 [TBL] [Abstract][Full Text] [Related]
42. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201 [TBL] [Abstract][Full Text] [Related]
43. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308 [TBL] [Abstract][Full Text] [Related]
45. Effect of lipoprotein apheresis on oxidative stress and antioxidant status in familial hypercholesterolemic patients. Kurtoglu E; Ugur A; Sait Gonen M; KiSakol G Int J Artif Organs; 2003 Nov; 26(11):1039-43. PubMed ID: 14708833 [TBL] [Abstract][Full Text] [Related]
46. [H.E.L.P. apheresis and oxidative stress]. Pulawski E; Mellwig KP; Horstkotte D Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600 [TBL] [Abstract][Full Text] [Related]
47. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Napoli C; Postiglione A; Triggiani M; Corso G; Palumbo G; Carbone V; Ruocco A; Ambrosio G; Montefusco S; Malorni A; Condorelli M; Chiariello M Atherosclerosis; 1995 Dec; 118(2):259-73. PubMed ID: 8770320 [TBL] [Abstract][Full Text] [Related]
48. Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation. Kritz H; Oguogho A; Aghajanian AA; Sinzinger H Prostaglandins Leukot Essent Fatty Acids; 1999 Sep; 61(3):183-8. PubMed ID: 10582658 [TBL] [Abstract][Full Text] [Related]
49. Selective continuous removal of low density lipoproteins by dextran sulfate cellulose column adsorption apheresis in the therapy of familial hypercholesterolemia. Stefanutti C; Isacchi GC; Antonini R; Bucci A; Cardillo A; Di Nucci GD; Gozzer M; Malagnino F; Masci M; Mazzarella B Beitr Infusionsther; 1988; 23():172-82. PubMed ID: 2484773 [No Abstract] [Full Text] [Related]
50. Effects of LDL apheresis on blood rheology in two patients with homozygous familial hypercholesterolaemia. Fadul JE; Sandhagen B; Linde T; Vessby B; Wikström B; Danielson BG Blood Purif; 1997; 15(3):182-7. PubMed ID: 9262844 [TBL] [Abstract][Full Text] [Related]
51. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis. McGowan MP J Clin Lipidol; 2013; 7(3 Suppl):S21-6. PubMed ID: 23642325 [TBL] [Abstract][Full Text] [Related]
53. Isolation of lipoprotein (a) using the regenerate of a dextran sulfate cellulose LDL apheresis system. Gross E; März W; Siekmeier R; Scharrer I; Gross W Protein Expr Purif; 1994 Apr; 5(2):112-7. PubMed ID: 8054842 [TBL] [Abstract][Full Text] [Related]
54. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Nishimura S; Sekiguchi M; Kano T; Ishiwata S; Nagasaki F; Nishide T; Okimoto T; Kutsumi Y; Kuwabara Y; Takatsu F; Nishikawa H; Daida H; Yamaguchi H Atherosclerosis; 1999 Jun; 144(2):409-17. PubMed ID: 10407502 [TBL] [Abstract][Full Text] [Related]
55. HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. Zanetti M; Zenti M; Barazzoni R; Zardi F; Semolic A; Messa MG; Mearelli F; Russi G; Fonda M; Scarano L; Bonora E; Cattin L PLoS One; 2014; 9(7):e101290. PubMed ID: 25014007 [TBL] [Abstract][Full Text] [Related]
56. LDL apheresis by dextran sulfate cellulose (DSC) column in two patients with monogenic familial hypercholesterolemia (FH). Aubert I; Bombail D; Erlich D; Goussault Y; Rouffy J; Bussel A Prog Clin Biol Res; 1990; 337():205-7. PubMed ID: 1693782 [No Abstract] [Full Text] [Related]
57. Evaluation of albumin loss during low-density lipoprotein apheresis. Kojima S; Shiba M; Nomura S; Kimura G; Tsushima M; Kuramochi M; Yamamoto A; Omae T ASAIO Trans; 1990; 36(4):830-3. PubMed ID: 2268488 [TBL] [Abstract][Full Text] [Related]
58. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053 [TBL] [Abstract][Full Text] [Related]
59. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Marangon K; Devaraj S; Tirosh O; Packer L; Jialal I Free Radic Biol Med; 1999 Nov; 27(9-10):1114-21. PubMed ID: 10569644 [TBL] [Abstract][Full Text] [Related]
60. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Chiu HC; Jeng JR; Shieh SM Biochim Biophys Acta; 1994 Jan; 1225(2):200-8. PubMed ID: 8280789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]